Last reviewed · How we verify
Linear tapering
Linear tapering is a dosing strategy that gradually reduces medication dose in a linear fashion over time to minimize withdrawal effects and allow physiological adaptation.
At a glance
| Generic name | Linear tapering |
|---|---|
| Sponsor | Universita di Verona |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Linear tapering is not a drug itself, but rather a pharmaceutical management approach used across multiple drug classes to safely discontinue or reduce medications. By decreasing the dose at a constant rate over a defined period, it allows the body to gradually readjust to lower drug exposure, reducing the risk of rebound effects, withdrawal symptoms, or disease relapse that might occur with abrupt discontinuation.
Approved indications
Common side effects
Key clinical trials
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases (PHASE3)
- Evaluation of Bioflex and Zirconia Crowns Versus Stainless Steel Crowns on Primary Molars: Randomized Controlled Clinical Trial (NA)
- Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy (PHASE2)
- Discontination of Antidepressants in Remitted Depression (PHASE4)
- Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) (PHASE2, PHASE3)
- Bilevel Erector Spinae Plane Block Versus Transversus Abdominis Plane Block for Analgesia After Cesarean Delivery. (NA)
- Bioceramic Putty Versus MTA in Pulpotomized Primary Teeth to be Covered With 3D Printed Resin Crowns Versus Stainless Steel Crown (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |